Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Novartis

Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal

Avidity Biosciences, Inc. (NASDAQ:RNA) shares are rocketing premarket on Monday. On Sunday, the company agreed to merge with Novartis AG (NYSE:NVS) in a deal valued at $12 billion on a fully diluted basis.

Benzinga

Novartis Cosentyx Trial Shows Efficacy In Patients With Stiff Joints And Muscle Pain

Novartis AG (NYSE:NVS) on Wednesday shared topline data from the Phase 3 REPLENISH trial of Cosentyx in patients with polymyalgia rheumatica.

Benzinga

Novartis Cancer Drug Shows Sustained Benefit In Five-Year Breast Cancer Trial

On Friday, Novartis AG (NYSE:NVS) shared results from the five-year analysis of the Phase 3 NATALEE trial of Kisqali (ribociclib).

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Novartis Strengthens Kidney Disease Pipeline With Promising Data

Novartis A/S (NYSE:NVS) on Thursday shared final results from the APPLAUSE-IgAN Phase 3 study evaluating Fabhalta (iptacopan) in adults with IgA nephropathy (IgAN).

Benzinga

Logitech CEO Hanneke Faber says she would consider adding an AI agent to her board of directors

Also: All the news and watercooler chat from Fortune.

Fortune

CEO says she’d welcome an AI-bot board member: ‘If you don’t have an AI agent in every meeting, you’re missing out’

Hanneke Faber speaks about the value of AI in decision-making at the Fortune Most Powerful Women Summit.

Fortune

Should You Buy Novartis Stock Before October 28?

Novartis is gaining traction this year, but can the trend continue?

Barchart

Read news from The Economist, FT, and more,
with one subscription

How high-cost Switzerland stayed a manufacturing powerhouse in the offshore era

What is the lesson of Swiss Fortune 500 companies—such as dsm-firmenich—for the rest of Europe, and the world?

Fortune

Pharma's Direct-To-Patient Wave Hits Novartis Next

The Pharmaceutical Research and Manufacturers of America (PhRMA) outlined initiatives to bolster U.S. manufacturing, ease patient costs, and improve access to medicine.

Benzinga

The Nations And Firms Threatened By Trump's Pharma Tariffs

Donald Trump has shocked the global drug industry by announcing 100-percent tariffs on all branded, imported pharmaceutical products -- unless companies are building manufacturing plants in the United States.

International Business Times

Trump’s latest tariff threat raises concerns for UK pharmaceuticals

Britain will ‘actively engage’ with US over possible 100% duties, with truck and cabinet makers also in firing line

The Guardian - UK

Novartis, AbbVie Face Legal Defeat Over 340B Contract Pharmacies

A U.S. federal judge has rejected challenges by two pharmaceutical manufacturers seeking to block a Maine law that regulates the use of contract pharmacies under the federal 340B drug discount program.

Benzinga

Novartis Builds US Drug Reserves Against Potential Tariffs

Novartis AG (NYSE:NVS) has reportedly built up its pharmaceutical stockpiles in the U.S. as a cushion against the potential impact of tariffs under consideration by the Trump administration, chief executive Vas Narasimhan said in a recent interview.

Benzinga

Novartis Chief Eyes Ways To End Higher US Drug Prices: Media

Amid a threat of towering US tariffs, Swiss pharmaceutical giant Novartis is seeking ways to enable Americans to pay less for their medicines, its chief said in an interview published Saturday.

International Business Times

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Big pharma firms have paused nearly £2bn in UK investments this year

Government’s plans in disarray before Trump talks as MSD, Eli Lilly and AstraZeneca moves prompt job fears

Benzinga

Monte Rosa, Novartis Use AI-Powered Engine To Advance Immune Disease Treatments

Monte Rosa Therapeutics Inc. (NASDAQ:GLUE) stock is surging on Monday, with a session volume of 11.67 million compared to the average volume of 408.08 thousand as per data from Benzinga Pro.

Benzinga

Trump's Biotech Playbook Ignites $350 Billion Investment Blitz

Biotech is back – and it's playing for keeps. President Donald Trump's second-term policies have unleashed a staggering ~$350 billion surge in U.S.-based pharmaceutical and biotech investments, from domestic manufacturing to cutting-edge RD. For investors, it's a rare opportunity: major drugmakers are expanding fast, and some could be poised to…

Benzinga

Tourmaline Bio, QMMM Holdings, Teck Resources And Other Big Stocks Moving Higher On Tuesday

U.S. stocks were lower, with the Nasdaq Composite falling around 0.1% on Tuesday.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver

Novartis is betting big on radioligand cancer therapy, but while the long-term growth story looks strong, NVS stock may face a short-term pullback

Benzinga

Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition

Tourmaline Bio, Inc. (NASDAQ:TRML) shares surged Tuesday after Novartis AG (NYSE:NVS) announced a $1.4 billion acquisition of the U.S.-based biotech, strengthening the Swiss drugmaker’s pipeline of cardiovascular and kidney treatments.

The National (Scotland)

Scotland becomes first in UK to screen babies for 'devastating' rare condition

Scotland is to become the first part of the UK to routinely screen newborn babies for a 'devastating' rare medical condition ...

Evening Standard

Scotland first part of the UK to screen babies for ‘devastating’ rare condition

From early 2026 it is expected babies born in Scotland will be routinely tested for Spinal Muscular Atrophy.

The Independent UK

Groundbreaking cholesterol jab could revolutionise heart disease care

Leqvio saw users achieve their target cholesterol levels faster than existing treatments

Evening Standard

Jab for high cholesterol could ‘transform’ heart care

Cholesterol is a fatty substance made by the liver and found in some foods.

Benzinga

Novartis Sees Hope In Reducing Lifelong Treatment Burden For Autoimmune Blood Disorder

Novartis AG (NYSE:NVS) released topline results on Tuesday from the VAYHIT2 Phase 3 trial evaluating ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.